Polikistik over sendromu - Hacettepe Üniversitesi Tıp Fakültesi

Piflkinpafla ve Y›ld›z
37. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome
and endometrial carcinoma. Lancet 2003; 361:1810-2.
38. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS.
Mortality of women with polycystic ovary syndrome at
long-term follow-up. J Clin Epidemiol 1998; 51:581-6.
39. Yildiz BO. Recent advances in the treatment of polycystic
ovary syndrome. Expert Opin Investig Drugs 2004; 13:
1295-305.
40. Yildiz BO, Chang W, Azziz R. Polycystic ovary syndrome
and ovulation induction. Minerva Ginecol 2003; 55:425-39.
41. Yarali H, Zeyneloglu HB. Gonadotrophin treatment in patients
with polycystic ovary syndrome. Reprod Biomed Online
2004; 8:528-37.
42. Gomel V, Yarali H. Surgical treatment of polycystic ovary
syndrome associated with infertility. Reprod Biomed Online
2004; 9:35-42.
43. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits
androgen production in human thecal cells. Fertil Steril
2001; 76:517-24.
44. Yarali H, Yildiz BO, Demirol A, et al. Co-administration of
metformin during rFSH treatment in patients with clomiphene
citrate-resistant polycystic ovarian syndrome: a prospective
randomized trial. Hum Reprod 2002; 17:289-94.
45. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative
risk of conversion from normoglycaemia to impaired
glucose tolerance or non-insulin dependent diabetes mellitus
in polycystic ovarian syndrome. Hum Reprod 2001;
16:1995-8.
46. Pasquali R, Casimirri F, Venturoli S, et al. Body fat distribution
has weight-independent effects on clinical, hormonal,
and metabolic features of women with polycystic ovary
syndrome. Metabolism 1994; 43:706-13.
47. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ.
Dietary composition in restoring reproductive and metabolic
physiology in overweight women with polycystic ovary
syndrome. J Clin Endocrinol Metab 2003; 88:812-9.
174
H ACETTEPE T IP D ERG‹S‹